Year All News20252024202320222021 Jun 25 2023 MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa Read More + May 12 2023 MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update Read More + May 3 2023 MoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply Read More + Apr 19 2023 MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today Read More + Mar 20 2023 MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update Read More + Feb 2 2023 MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa Read More + Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Displaying 11 - 16 of 16
Jun 25 2023 MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa Read More +
May 12 2023 MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update Read More +
May 3 2023 MoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply Read More +
Apr 19 2023 MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today Read More +
Mar 20 2023 MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update Read More +
Feb 2 2023 MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa Read More +